SecBot SecBot
8-K ·Filed May 14, 2026

APLS

Apellis Pharmaceuticals, Inc.
BULLISH
Impact 8/10
Horizonimmediate Processed6mo ago SEC0001193125-26-222923
Killer combo: M&A completed + management change
Actionable Insight ▲ Bullish

The acquisition is complete, APLS shares are delisted and no longer trade. Holders who tendered will receive $41.00 cash plus CVRs. The CVRs are non-transferable and trade only via limited permitted transfers; monitor SYFOVRE sales trajectories for potential milestone triggers. Note holders should evaluate conversion vs. repurchase options by June 29, 2026.

DirectionBullish
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK AT ENTRY AT T+1
Entry
$41.03
T+0 close · May 14, 2026 · via day close
Latest settled
0.00%
T+1 · $41.03
Vs SPY
+1.23%
α at T+1
Next horizon
T+5
due 6mo ago
  1. T+0 · May 14 $41.03entry
  2. T+1 · 6mo ago 0.00%α +1.23% · $41.03
  3. T+5 · due 6mo ago Pending
  4. T+20 · due 5mo ago Pending
  5. T+60 · due 3mo ago Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Biogen completed its acquisition of Apellis Pharmaceuticals on May 14, 2026, through a tender offer and subsequent merger. Apellis stockholders received $41.00 per share in cash plus one contingent value right (CVR) per share, with potential milestone payments of up to $4.00 per CVR tied to SYFOVRE sales targets. The deal valued at approximately $5.3 billion, and APLS common stock has been delisted from Nasdaq, with the company now a wholly owned subsidiary of Biogen.

Key Financial Metrics

Deal Value
$5.3B
Deal Type
merger

Key Facts

  • Biogen completed acquisition of Apellis for $41.00 per share in cash plus one CVR per share (up to $4.00 additional per CVR tied to SYFOVRE sales milestones).
  • Total deal value approximately $5.3 billion, excluding potential CVR payments.
  • 105,687,831 shares (82.4% of outstanding) were validly tendered in the offer.
  • CVR milestones: $2.00 per CVR if SYFOVRE annual net sales reach $1.5B in 2027-2030; $2.00 per CVR if sales reach $2.0B in 2027-2031 (or $4.00 if first milestone missed but second achieved in 2031).
  • Biogen estimates maximum CVR payout of approximately $582 million if all milestones achieved.
  • APLS common stock delisted from Nasdaq; company now a wholly owned subsidiary of Biogen.
  • All directors resigned; Michael Dambach appointed as sole director.
  • Convertible notes (3.500% due 2026) converted to cash and CVRs; holders have repurchase right at ~$1,008.46 per $1,000 principal.

Financial Impact

Total deal value ~$5.3B cash plus up to ~$582M in potential CVR payments (max ~$4.00/share).

revenuedilutiondebt

Risk Factors

  • CVR milestones may not be achieved; maximum payout requires SYFOVRE annual sales of $1.5B-$2.0B by 2030-2031.
  • CVRs are non-transferable and illiquid, no secondary market.
  • Convertible note holders face complex election between conversion (cash + CVRs) and repurchase at ~$1,008.46/principal.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
30% bullish (27 analysts)

Investment Themes

Documents Analyzed

This report is based on 9 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-222923
Document: d23709d8k.htm0001193125-26-222923
Document: d23709dex32.htm0001193125-26-222923
Document: d23709dex31.htm0001193125-26-222923
Document: d23709dex991.htm0001193125-26-222923
Document: d23709dex41.htm0001193125-26-222923
Document: 0001193125-26-222923-index-headers.html0001193125-26-222923
Document: 0001193125-26-222923-index.html0001193125-26-222923
Document: 0001193125-26-222923.txt0001193125-26-222923

Track record

5 reports on APLS

Performance horizon
Filters
  1. May 26, 202624w ago 15-12G Neutral 6/10 No price data
  2. May 14, 202626w ago 25-NSE Neutral 2/10 Entry $41.03 to $41.03 · 0.00% +1.23% vs SPY
  3. May 14, 202626w ago 8-K Bullish 8/10 Viewing Entry $41.03 to $41.03 · 0.00% +1.23% vs SPY
  4. May 4, 202628w ago 8-K Neutral 2/10 Entry $40.97 to $40.97 · 0.00% −0.80% vs SPY
  5. Mar 27, 202633w ago Institutional Cluster Mixed 6/10 Entry $16.97 to $17.09 ▲ +0.71% +1.06% vs SPY
Showing 5 of 5

US Market Status

Market Closed · Opens Wed (10h 19m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 14, 2026